Search Results 1391-1400 of 10658 for total t4
All patients who complete the 52-week double-blind treatment period on IP may be eligible to continue into an open label extension (OLE) period. The OLE ...
Related. Associated Procedures. Complete blood count (CBC) · Splenectomy. Products & Services. A Book: Mayo Clinic Family Health Book · Newsletter: Mayo Clinic ...
The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk ...
The purpose of this study is to evaluate the Maximum Tolerated Dose (MTD) of pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and ...
About this study. This research study is for liver transplant recipients and their respective living donors. The purpose of this study is to see if it is ...
Total bilirubin >1.5 × ULN with the exception of participants with the diagnosis of Gilbert's syndrome who may be eligible provided they have no other ...
Complete blood count values prior to Day 1 of HCT < 45% or of HCT < 48% if followed by a phlebotomy within 2 weeks prior to baseline, white blood cells 4000 ...
Rochester, Minn. The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
The primary objective of the study is to evaluate the Overall Survival (OS). Pagination Clinical studies. PrevPrevious Page · Go to page 22 · Go to page 33 · Go ...
Participation eligibility · Patients must not be candidates for allogeneic hematopoietic stem cell transplant. · Patients must have complete history and physical ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.